TuisBNTX • NASDAQ
add
BioNTech SE ADR
Vorige sluiting
$109,26
Dagwisseling
$109,43 - $111,07
Jaarwisseling
$79,88 - $131,49
Markkapitalisasie
26,50 mjd USD
Gemiddelde volume
680,64 k
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 260,80 m | 102,64% |
Bedryfskoste | 621,10 m | -39,74% |
Netto inkomste | -386,60 m | 52,14% |
Netto winsgrens | -148,24 | 76,38% |
Wins per aandeel | -1,60 | 52,38% |
EBITDA | -385,70 m | 57,70% |
Effektiewe belastingkoers | 4,00% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 14,04 mjd | -18,84% |
Totale bates | 21,64 mjd | -2,70% |
Totale aanspreeklikheid | 3,13 mjd | -1,05% |
Totale ekwiteit | 18,51 mjd | — |
Uitstaande aandele | 240,40 m | — |
Prys om te bespreek | — | — |
Opbrengs op bates | -5,10% | — |
Opbrengs op kapitaal | — | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -386,60 m | 52,14% |
Kontant van bedrywe | — | — |
Kontant van beleggings | -64,40 m | 73,32% |
Kontant van finansiering | -13,30 m | 41,92% |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | -292,96 m | -116,69% |
Meer oor
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
HUB
Gestig
2008
Webwerf
Werknemers
6 772
